Back to search results

Propranolol with Chemoradiation for Esophageal Adenocarcinoma

This study is looking at how safe and effective a drug called propranolol is when given along with standard treatments like chemotherapy (Carboplatin, Paclitaxel) and radiation therapy (3 Dimensional Conformal Radiation Therapy or Intensity Modulated Radiation Therapy) for esophageal adenocarcinoma. The study aims to see if adding propranolol, which works by affecting your immune system, can improve outcomes. You might be able to join if you are 18 or older, have esophageal adenocarcinoma, and can swallow oral medications. The researchers will be tracking side effects and how long patients live without their cancer getting worse for up to five years. The current recruitment status is unclear.

Study design
This is a Phase II interventional study with a planned enrollment of 106 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the occurrence of adverse events and progression-free survival for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04682158

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Roswell Park Cancer Institute
~106 participants
Updated 2026-01-02 on ClinicalTrials.gov
What's tested:Carboplatin3 Dimensional Conformal Radiation TherapyPropranololIntensity Modulated Radiation TherapyPaclitaxel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of Adverse Events
Measured over Up to 5 years
+1 more outcome measured

Conditions

Esophageal Adenocarcinoma

Explore related trials

Esophageal Adenocarcinoma

NCT04682158

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Roswell Park Cancer Institute

    Buffalo, New Yorkno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Anurag Singh, MD · PRINCIPAL_INVESTIGATOR · Roswell Park Cancer Institute

Who to contact

ASK RPCI
[email protected]
1-800-767-9355
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Undergoing definitive or neoadjuvant CRT for histologically confirmed esophageal adenocarcinoma
Have an ECOG performance status of 0-1
Have the ability to swallow and retain oral medication. If a patient is not able to swallow, they are still eligible for study provided they have an enteric feeding placed which will permit administration of crushed tablets or liquid formula propranolol prior to first radiation treatment
Participants of child-bearing potential must have a negative pregnancy test at study entry And then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. - Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion

Contraindications to the use of beta-blockers, e.g.; uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (New York Heart Association (NYHA) Grade III or IV), hypotension ( systolic blood pressure \<100 mmHg), severe asthma or COPD, uncontrolled type I or type II diabetes mellitus (HbA1C \>8.5 or fasting plasma glucose \> 160 mg/dL at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current calcium channel blocker use (Non-dihydropyridines such as verapamil) or rhythm control agents such as digoxin and amiodarone. Patients with pacemakers will be excluded
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,symptomatic congestive heart failure, unstable angina pectoris, psychiatric illness/social situations that would limit compliance with study requirements, cardiac arrhythmia (atrial fibrillation/flutter), severe bradycardia (heart rate of \<50 beats per minute or 1st/ 2nd /3rd degree heart block)
Pregnant or nursing female participants,
Unwilling or unable to follow protocol requirements
Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug

What this trial measures

  • Occurrence of Adverse EventsUp to 5 years

    To determine the safety and efficacy of the combination of propranolol plus chemoradiation

  • Progression Free SurvivalUP to 5 years

    Imaging findings from first radiation treatment to progression of disease